J&J Braces For Health Care Reform Hit, But Can "Accommodate" Impact
This article was originally published in The Pink Sheet Daily
Executive Summary
J&J's 2010 sales will be $400 million to $500 million lower due to health care reform, although J&J didn't significantly lower 2010 earnings as a result.
You may also be interested in...
For Bristol, Onglyza Disappoints And Health Care Reform Takes A Toll
The new health care reform statute will have a significant impact on Bristol-Myers Squibb's sales in 2010 and 2011, the company said during a first quarter sales and earnings call April 29 in which the drug maker announced it is revising earnings guidance for the year as a result
For Bristol, Onglyza Disappoints And Health Care Reform Takes A Toll
The new health care reform statute will have a significant impact on Bristol-Myers Squibb's sales in 2010 and 2011, the company said during a first quarter sales and earnings call April 29 in which the drug maker announced it is revising earnings guidance for the year as a result
For BMS, Onglyza Disappoints And Health Care Reform Takes A Toll
The health care reform law, which will lower Bristol-Myers Squibb's sales by $350 million to $400 million this year, led the firm to revise earnings guidance.